RNA Disease Diagnostics (RNADD) was formed to create a best-in-class rapid, accurate and low-cost molecular diagnostic technology platform that will democratize point of care testing and contribute to the prevention of infectious disease transmission and to better the health of the citizens of the world. The Company plans to leverage its proprietary Electrochemical and AntiSense Oligonucleotide (ASO) RNA molecular diagnostic platform across multiple diseases. Working with the University of Maryland, Baltimore (UMB) and the University of Maryland, Baltimore County (UMBC) RNADD has secured an exclusive global license to this cutting-edge molecular sensor technology.
RNADD’s initial focus is to develop and deploy its proprietary molecular diagnostic technology at the Point Of Care (POC). The Company operates out of New York, California and Toronto, Canada.
Mike C. Kaufmann recently joined the Board of Directors of RNA Disease Diagnostics, Inc. (RNADD). Mike is a former Fortune 15 CEO and CFO, and an active advocate and executive speaker on leadership and diversity, equity, and inclusion (DE&I).Read MoreRead More
RNA Disease Diagnostics, Inc. (“RNADD” or the “Company”), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care (“POC”) and home-use infectious disease detection, announced today the appointments of its Chief Scientific Advisor, Professor Dipanjan Pan, M.S., Ph.D., and its President, John W. Erickson, Jr., to the Company’s Board of Directors.Read MoreRead More